Skip to main content

Building

A better future

through education, skill development and research

LEARN MORE

Do Pain Medications Carry Different Heart Risks?

Prior studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may be linked with higher cardiovascular risks, but few have assessed potential different cardiovascular risk between NSAID classes or across individual NSAIDs.

Thursday, February 22, 2018 12:01 am EST
"Our results provide important information about the comparative safety of alternative NSAID use in patients with hypertension in real-world settings. Under low-to-moderate daily dose and a short-term treatment period, most commonly used NSAIDs have similar cardiovascular safety profiles"

Prior studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may be linked with higher cardiovascular risks, but few have assessed potential different cardiovascular risk between NSAID classes or across individual NSAIDs.

A British Journal of Clinical Pharmacology study including 55,629 patients with hypertension in a Taiwanese database did not observe different cardiovascular risks in patients who received cyclooxygenase-2 enzyme selective NSAIDs or nonselective NSAIDs during 4 weeks of follow-up.

The study also found no apparent difference in cardiovascular risk when comparing celecoxib with diclofenac, ibuprofen, or naproxen, although a significantly increased risk was observed when comparing celeocxib with mefenamic acid. 

“Our results provide important information about the comparative safety of alternative NSAID use in patients with hypertension in real-world settings. Under low-to-moderate daily dose and a short-term treatment period, most commonly used NSAIDs have similar cardiovascular safety profiles,” said co-author Dr. Chia-Hsuin Chang, of the National Taiwan University Hospital.


Additional Information

Link to Study: http://onlinelibrary.wiley.com/doi/10.1111/bcp.13537/full

About Journal

The British Journal of Clinical Pharmacology (BJCP) contains papers and reports on all aspects of drug action in humans: invited review articles, original papers and correspondence. The journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry.

Multimedia Files:

Preview image

Contact:

Penny Smith
+44 (0) 1243 770448
sciencenewsroom@wiley.com

Business Wire NewsHQsm